《国际循环》：ACCORD试验显示，在血糖控制良好的前提下，将收缩压降至120 mmHg以下与140 mmHg以下相比，不能进一步减少心血管事件的发生。您如何看待这一研究结果？
     Luis Kuritsky教授：对于血压已经降至130/80 mmHg的患者，可以维持目前的血压水平，我们知道这不会给患者带来任何坏处。但是，对于血压未达到130/80 mmHg的患者，我们没理由为了把血压降到130/80 mmHg让患者承担用药更多、不良反应更多和耐受性更差的风险。目前，可以确定的是，将血压降到140/90 mmHg以下是有好处的。但是，除了血压之外，糖尿病患者同时还有很多指标需要达标，我们没有必要对他们过度严格地降压，这会使他们的生活变得过为复杂。  

     <International Circulation>: The ACCORD trial suggests that a therapeutic strategy that targets a systolic blood pressure of <120 mm Hg in the context of good glycemic control can not reduce the rate of CVD events compared with a strategy that targets a systolic blood pressure of <140 mm Hg. What is your view of these results?

    Prof. Kuritsky: For patients who have already achieved the previously recommended goal， we can leave them there knowing that they have not suffered any adversity but for persons who are not yet to that prior goal of 130/80 mmHg， this data would suggest that we do not have the justification to cost them the additional burden of more medicine， more expense， more side effects， and less tolerability. We can now be confident that we are still doing well by reducing blood pressure less than 140/90 mm/Hg， but there is no need in a patient a population that is already suffering with many goal attainments at the same time to complexify their lives by pushing harder on their blood pressure.